Feb. 9 at 1:06 PM
$NOTV
🚨 🚨 🚨
Revenue:
$120.9 million, a 0.8% increase year-over-year, but below the
$126.53 million analyst estimate.
EPS (Diluted): -
$0.83, missing the estimated -
$0.51.
Net Loss:
$28.4 million.
Adjusted EBITDA:
$1.8 million.
Operational & Business Notes
The decline in the Research Models and Services (RMS) segment was primarily due to lower non-human primate volumes.
The Discovery and Safety Assessment (DSA) segment saw net awards increase by 27% compared to the previous year.
Cash and cash equivalents decreased to
$12.7 million as of December 31, 2025, and total debt stood at
$405.8 million.
